NCT01150123View on ClinicalTrials.gov

Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women

PHASE1CompletedINTERVENTIONAL
Enrollment

678

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

November 30, 2011

Study Completion Date

October 31, 2012

Conditions
Group B Streptococcus
Interventions
BIOLOGICAL

Group B streptococcus (GBS) vaccine- low dose

BIOLOGICAL

Group B streptococcus (GBS) vaccine- High dose

BIOLOGICAL

Placebo- Saline

Trial Locations (1)

Unknown

Ghent

Sponsors

Lead Sponsor

Novartis Vaccines

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Novartis Vaccines

INDUSTRY

NCT01150123 - Safety and Immunogenicity of a Group B Streptococcus Vaccine in Healthy Women | Biotech Hunter | Biotech Hunter